Therefore, further studies on the effect of IL-6 blockers in ovarian cancer are needed and elucidating the correlation between IL-6 activated STAT3 phosphorylation and FoxO3a may suggest and exciting new therapeutic directions. This evidence concerns the gene STAT3 and ovarian carcinoma.